This site is intended for healthcare professionals
Latest industry news
  • Home
  • /
  • News
  • /
  • 2023
  • /
  • 9
  • /
  • POINT Biopharma collaborates with Athebio AG to de...

POINT Biopharma collaborates with Athebio AG to develop DARPin-targeted radioligands

Read time: 1 mins
Published:19th Sep 2023

POINT Biopharma Global Inc. a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, and Athebio AG , an innovation leader in the discovery and design of designed ankyrin repeat proteins (DARPins), announced a collaboration and license agreement to develop and commercialize DARPin-targeted radioligands (“Radio-DARPins”).

DARPins are an attractive ligand class for cell-surface targets that could enable access to cell “surfaceome” targets beyond catalytic and ligand binding sites typically accessible to small molecules and peptides. DARPins combine the small molecule feature of rapid tumor penetration and clearance from the body, with the antibody-like ability of binding to a wider range of proteins and other cell surface targets. Their well-behaved and customizable formatting options, including stability at high concentrations and temperatures, are expected to facilitate rapid discovery, validation, and commercial scale manufacturing applicable to fast (212Pb) and slower (177Lu, 225Ac) decaying isotopes. The collaboration gives POINT exclusive access to Athebio’s intellectual property and capabilities in DARPin development in the radioligand therapy field. Together, the parties will collaborate in discovery, candidate selection and preclinical development of Athebody DARPins for use as Radio-DARPin drug entities. POINT will be solely responsible for the clinical development and commercialization of Radio-DARPins translated from the discovery collaboration.

Type: industry

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.